TrialNature cancer2023

Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC.

Caicun Zhou et al.PubMed ↗Publisher ↗

No numbers read from the abstract.